Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

JLL Partners, Inc.'s Affiliate Commences Cash Tender Offer To Acquire BioClinica Inc


Monday, 11 Feb 2013 07:30am EST 

BioClinica Inc and JLL Partners, Inc. announced that BC Acquisition Corp. (Purchaser), which is a wholly owned subsidiary of BioCore Holdings, Inc. (Parent), each of which is an affiliate of JLL, has commenced a tender offer for all outstanding shares of BioClinica at a price of $7.25 per share net to the seller in cash. The offer is being made pursuant to a definitive merger agreement pursuant to which Parent will acquire BioClinica. Parent and Purchaser are affiliates of JLL Partners Fund VI, L.P. (the Sponsor), which is a private equity investment fund managed by JLL. The Board of Directors of BioClinica has unanimously approved and declared advisable the merger agreement. The tender offer, will be followed by a second-step merger in which any shares of BioClinica not tendered into the offer will be converted into the right to receive the same per share consideration paid to BioClinica stockholders in the tender offer. There is no financing condition for the tender offer. Unless the tender offer is extended, the tender offer and any withdrawal rights to which BioClinica's stockholders may be entitled will expire at 12:00 midnight, New York City time at the end of March 11, 2013. Following the acceptance for payment of shares in the tender offer and completion of the transactions contemplated in the merger agreement, BioClinica will become a wholly owned subsidiary of Parent. 

Company Quote

2.95
 --
25 Nov 2014